Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
West Pharmaceutical Services (NYSE: WST) announced its participation in the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference on October 18, 2022. The company aims to showcase its expertise in drug delivery innovation, focusing on challenges in packaging and containment. Cindy Reiss-Clark, Chief Commercial Officer, highlighted the importance of evolving healthcare needs and technological advancements. West will present several technical sessions, including topics on customized injection profiles and sustainable device selection. In fiscal year 2021, West generated $2.83 billion in net sales.
West Pharmaceutical Services (NYSE: WST) will announce its third-quarter 2022 financial results before market opens on October 27, 2022. Following the announcement, a conference call will be held at 9:00 a.m. Eastern Time to discuss the results and future business expectations. The live audio webcast will be available on the company's Investor Relations website. Interested participants can register in advance to ask questions during the call. A replay will be accessible for 30 days post-event.
West Pharmaceutical Services (NYSE: WST) has been shortlisted for the 2022 Global Generics and Biosimilar Awards, with the winner to be announced on November 2, 2022, at CPhI Worldwide in Frankfurt, Germany. This recognition underscores West's commitment to enhancing patient care through innovative drug delivery solutions. In fiscal year 2021, West achieved net sales of $2.83 billion, reflecting its position as a key player in the injectable solutions market.
West Pharmaceutical Services, traded on NYSE: WST, will participate in the Bank of America Global Healthcare Conference on September 15, 2022, at 1:20 pm BST in London, UK. A live audio webcast will be accessible via the company's website, with a replay available for 90 days post-event. West, a leader in injectable drug solutions, generated $2.83 billion in net sales in 2021 and employs approximately 10,000 team members globally.
West Pharmaceutical Services (NYSE: WST) announced a minority investment in Latch Medical, a Dublin-based innovator in vaccine and biologics delivery technology, on August 11, 2022. This strategic move aims to enhance West's leadership in patient-focused innovations. Latch Medical's Pharma Latch technology offers cost-effective intradermal delivery systems for vaccines, utilizing microneedles for improved dosing. West’s investment aligns with its commitment to drive innovation in healthcare delivery, emphasizing improved patient outcomes.
West Pharmaceutical Services reported Q2 2022 net sales of $771.3 million, a 6.6% increase, with organic growth at 13.1%. Diluted EPS was $2.48, slightly up from $2.47 year-over-year. The company revised its full-year 2022 net sales guidance to $2.950-$2.975 billion from $3.050-$3.075 billion, citing a decline in COVID-19 related sales. Adjusted-diluted EPS guidance was also lowered to $9.00-$9.15. Proprietary Products showed robust growth, while Contract-Manufactured Products saw a 13.6% decline in sales.
West Pharmaceutical Services, Inc. (NYSE: WST) has elected Stephen Lockhart, M.D., Ph.D., to its Board of Directors, expanding the board to 11 members. Dr. Lockhart, a veteran physician and former Chief Medical Officer of Sutter Health, brings over 20 years of healthcare experience. His leadership background includes roles in quality, patient safety, and health equity advancements. West generated over $2.83 billion in sales in FY 2021 and boasts a global workforce of approximately 10,000 employees. This appointment is expected to enhance West's strategic direction in delivering innovative healthcare solutions.
West Pharmaceutical Services (NYSE: WST) will release its second-quarter 2022 financial results before the market opens on July 28, 2022. Following this, a conference call is scheduled for 9:00 a.m. Eastern Time to discuss the results and future business expectations. A live audio-only webcast will be accessible via the Company’s Investor Relations website. Participants can register in advance to pose questions during the call. A replay will be available for 30 days post-event. West is a leader in innovative injectable solutions, generating over $2.83 billion in sales in 2021.
West Pharmaceutical Services (NYSE: WST) has published its 2021 Corporate Responsibility Report, highlighting significant progress in environmental sustainability, diversity, and philanthropic efforts. Key achievements include the establishment of an ESG Steering Committee, an increase in waste diversion from landfills to 85%, and a 72% rise in employee giving. Notably, 64% of the Executive Team comprises women or U.S. minorities. The report aligns with global sustainability standards, reinforcing West's commitment to improving patient lives while managing its corporate responsibilities.
West Pharmaceutical Services (NYSE: WST) announced the launch of its new Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at the BIO International Convention in San Diego, CA, from June 13-16, 2022. This advanced syringe system is an expansion of the existing 1mL version, designed to facilitate larger volume injections, thereby enhancing patient experience by potentially reducing the number of injections needed. The partnership with Daikyo allows for global distribution of this innovative product.